The estimated Net Worth of David O. Watson is at least $6.3 Milión dollars as of 6 March 2024. Mr. Watson owns over 3,762 units of Apellis Pharmaceuticals Inc stock worth over $4,110,351 and over the last 5 years he sold APLS stock worth over $2,185,303. In addition, he makes $0 as General Counsel a Vice President of Corporate Development at Apellis Pharmaceuticals Inc.
David has made over 21 trades of the Apellis Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 3,762 units of APLS stock worth $52,104 on 6 March 2024.
The largest trade he's ever made was exercising 43,483 units of Apellis Pharmaceuticals Inc stock on 27 January 2021 worth over $174,367. On average, David trades about 4,828 units every 51 days since 2019. As of 6 March 2024 he still owns at least 107,152 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Mr. Watson stock trades at the bottom of the page.
David O. Watson serves as General Counsel, Vice President of Corporate Development of the Company. From January 2014 to June 2015, Mr. Watson also served as general counsel and executive vice president of Revon. From 2006 to December 2013, Mr. Watson was a member at the law firm Frost Brown Todd LLC. Mr. Watson received his B.A. from Harvard College, his J.D. from Vanderbilt Law School and his M.A. in mathematics from the University of Kentucky.
David Watson is 47, he's been the General Counsel a Vice President of Corporate Development of Apellis Pharmaceuticals Inc since 2014. There are 16 older and 4 younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.
David's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC, 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois a Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: